Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204455 | 1.00 | HCAR2 (0.35) | HCAR2KEAP1NFE2L2GLRA1SLC6A9 | |
| SCHEMBL558370 | 0.91 | — | — | |
| SCHEMBL10602462 | 0.91 | HCAR2 (0.45) | HCAR2GLRA1SLC6A9OR51E2GABRR1 | |
| SCHEMBL10602450 | 0.91 | HCAR2 (0.45) | HCAR2GLRA1SLC6A9OR51E2GABRR1 | |
| SCHEMBL28548482 | 0.85 | GSTP1 (0.31) | LMNAKDM4E | |
| SCHEMBL4587745 | 0.79 | — | — | |
| SCHEMBL288431 | 0.78 | — | — | |
| Potassium SCHEMBL31261840 | 0.77 | TSHR (0.38) | TSHR | |
| SCHEMBL6753492 | 0.76 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| SCHEMBL6258848 | 0.76 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357533-B2 | Drug for the effective control of acute and or chronic pain and a method for its administration | PVP LaBs PTE, Ltd. (SG) | 2019-07-23 | — | — | US | claimed |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20120035320-A1 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2012-02-09 | — | — | US | disclosed |
| US-3954858-A | Novel sequestrant builders and method of making the same | LEVER BROTHERS COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035320-A1 | POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES | NUP205, PABPC1, SARNP | HCAR2 3108/4885KEAP1 2990/4885NFE2L2 3466/4885 |
| US-20190225587-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | IDO2, MKI67, IDO1 | HCAR2 493/4885KEAP1 1087/4885NFE2L2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.